MGC Pharmaceuticals Ltd.
| MGC Pharmaceuticals Ltd. | |
| Traded as | ASX: MXC |
| ISIN | 🆔 |
| Industry | Pharmaceuticals and Medical Research |
| Founded 📆 | 2005 |
| Founder 👔 | |
| Headquarters 🏙️ | , Europe and Australia |
Area served 🗺️ | |
| Members | |
Number of employees | |
| 🌐 Website | https://mgcpharma.com.au/ |
| 📇 Address | |
| 📞 telephone | |
MGC is an EU based bio-pharmaceutical company founded in 2005 by Roby Zomer and Nativ Segev.[1] MGC Pharmaceuticals is also a publicly traded company in the Australian Stock Exchange as MXC.[2][3][4] The company's core business is a seed to pharmacy pipeline, which develops and supplies high-quality cannabinoid-based pharmaceutical products to medical markets globally.[5][6]
Overview
MGC Pharmaceuticals uses cannabis ingredients (cannabinoid) to treat diseases such as Epilepsy and Dementia.[5][7] It has collaborated with the Royal Melbourne Institute of Technology in Australia on a project to oversee cannabis research activities at the institute.[8][9][10]
MGC has published several whitepapers dealing with medical cannabis to treat epilepsy, cancer, and multiple sclerosis.[11][12] MGC Pharma signed a 5-year, supply and distribution agreement with European pharmaceutical distribution company, Lenis Farmacevtika.[13][9][14] MGC received legal permission for the sale of cannabis based medicine for medical use in Australia's new market.[15][16][17] MGC Pharma sells MGC Derma business to strategic partners with a five year supply agreement for MGC Pharma's cannabidiol (CBD) and cosmetics raw material to Cannaglobal products.[18][19][20][21][22]
Revenue
MGC sponsored CannaTechUK 2017 held at the Old Truman Brewery in East London's arts and media quarter in October.
MGC Pharma added 31.37%[23] to its share price after its CannEpil medical cannabis product received an Australian Therapeutic Goods Administration approval for reimbursement to people with drug-resistant epilepsy.[5] The firm raised over $5 million through a share placement to professional investors at 7 cents per share.[24][25]
Awards
MGC has been awarded a contract by the government of Malta to construct a 4000 square meter state-of-the-art medical cannabis production and cultivation facility.[12][26]
References
- ↑ "Cannabis rising: Finfeed Q&A with MGC Pharma managing director Nativ Segev". Finfeed. 2016-08-30. Retrieved 2019-08-05.
- ↑ "MGC Pharmaceuticals - MXC". Stockhead. Retrieved 2019-08-09.
- ↑ Kalkine, Team (2019-06-17). "Medicinal Cannabis Products & Some Publicly Traded Companies- MXC,AC8,CAN,CPH & THC". Kalkine Media. Retrieved 2019-08-09.
- ↑ July 13, James Mickleboro |; MXC, 2018 | More on (2018-07-13). "Why cannabis company MGC Pharmaceuticals Ltd (ASX:MXC) rocketed higher today". Motley Fool Australia. Retrieved 2019-08-05.
- ↑ 5.0 5.1 5.2 "MGC Pharma receives TGA approval to market epilepsy drug in Australia". www.biospectrumasia.com. Retrieved 2019-08-01.
- ↑ "MGC Pharma smashes major milestones". Finfeed. 2018-08-06. Retrieved 2019-08-05.
- ↑ Tatiana (2018-12-27). "First Australian CBD-Based Epilepsy Drug". GMP news. Retrieved 2019-08-05.
- ↑ "MGC secures permit to import epilepsy drug into the UK". The West Australian. 2019-04-12. Retrieved 2019-08-09.
- ↑ 9.0 9.1 "MGC Pharma on track for Europe medical cannabis site". The West Australian. 2017-02-21. Retrieved 2019-08-01.
- ↑ "MGC Pharma taps RMIT to build 'Google of medicinal cannabis'". iTnews. Retrieved 2019-08-09.
- ↑ "MGC Pharmaceuticals rockets up 37% after reimbursement win for cannabis epilepsy therapeutic". Proactiveinvestors UK. 2018-10-11. Retrieved 2019-08-05.
- ↑ 12.0 12.1 Jalimnson, Gillian (2016-03-29). "White Paper: Medicinal Cannabis in Australia". Hemp Gazette. Retrieved 2019-08-01.
- ↑ Report, Special (2018-09-06). "Distribution deal opens new international opportunities for MGC Pharma". Stockhead. Retrieved 2019-08-05.
- ↑ "MGC jumps after securing new European Cannabis license". The West Australian. 2017-06-05. Retrieved 2019-08-05.
- ↑ Thursday, Matt Birney; September, 6; 2018 - 15:26 (2018-09-06). "MGC signs European medical cannabis deal". Business News. Retrieved 2019-08-05.
- ↑ "High demand: CBD-based products gain popularity in European markets". www.europeanceo.com. Retrieved 2019-08-05.
- ↑ "Strategic Cannabis Acquisition Complete: MXC Set to Break Ground in Europe, Australia the Next Step". Next Biotech. 2017-02-23. Retrieved 2019-08-05.
- ↑ "MGC Pharma gets green thumbs up from Maltese government for cannabis facility - MaltaProfile.info". maltaprofile.info. Retrieved 2019-08-05.
- ↑ Monday, Matt Birney; January, 29; 2018 - 09:41 (2018-01-29). "MGC Pharma gets green light for European cannabis facility". Business News. Retrieved 2019-08-05.
- ↑ "MXC to Build Malta Production Facility to Capitalise on $55B Global Pot Market". Next Biotech. 2018-04-12. Retrieved 2019-08-05.
- ↑ "Budding ASX Junior Pens Transformative Medical Cannabis Deals: Now Generating Revenue". Next Biotech. 2017-11-23. Retrieved 2019-08-05.
- ↑ Report, Special (2018-09-27). "MGC Pharma to sell MGC Derma business to strategic partner". Stockhead. Retrieved 2019-08-05.
- ↑ "MGC Pharmaceuticals Ltd". MarketWatch. Retrieved 2019-08-01.
- ↑ Jalimnson, Gillian (2016-09-22). "Treating Epilepsy, Cancer And MS With Cannabis - Clinical Evidence". Hemp Gazette. Retrieved 2019-08-01.
- ↑ "MGC Pharmaceuticals attracts $5 million for medical cannabis facility in Malta". Proactiveinvestors UK. 2018-04-11. Retrieved 2019-08-09.
- ↑ Major EU Pharma Supply Agreement Signed with Lenis (PDF). Search this book on
External links
This article "MGC Pharmaceuticals" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:MGC Pharmaceuticals. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
|
This page exists already on Wikipedia. |
